Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.1 USD | -0.87% | -1.07% | -13.40% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |